You are here: Industry Insights > ADC

News List

CStone and LegoChem to jointly develop novel antibody drug conjugate pharmaceutical-technology
October 30, 2020
CStone Pharmaceuticals and LegoChem Biosciences (LCB) have signed a licensing agreement for the development and commercialisation of a potential antibody-drug conjugate (ADC), LCB71.
Iksuda Therapeutics exercises licensing rights from University of Goettingen pharmatimes
October 16, 2020
UK-based biotech company Iksuda Therapeutics has executed its option to secure exclusive worldwide rights to develop a new class of tumour-activated prodrug payloads from the University of Goettingen.
Exelixis, NBE join forces for discovery and development of ADCs for cancer pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...
$65 million expansion to HPAPI manufacturing facility europeanpharmaceuticalreview
September 24, 2020
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities contractpharma
September 18, 2020
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.
Exelixis and Catalent Enter ADC Partnership contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.
Abzena Receives $10M Investment from Biospring Partners contractpharma
July 29, 2020
New capital will allow Abzena to further accelerate its growth plans. Abzena drove 80% revenue growth and tripled GMP manufacturing capacity in 1H20.
Trio Pharmaceuticals, Ajinomoto Bio-Pharma Announce Antibody Therapeutic Collaboration americanpharmaceuticalreview
May 04, 2020
Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services announced a development collaboration agreement to evaluate AJICAP™.
OBI Pharma Granted Orphan Drug Designation for ADC Targeted Cancer Therapy americanpharmaceuticalreview
January 06, 2020
OBI Pharma announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Pancreatic Cancer. OBI-999 is a first-in-class antibody drug conjugate targeting Globo H, a glycolipid antigen.
MabPlex Lauded by Frost & Sullivan for Global Expansion of ADC Contract Manufacturing Services En-CPhI.CN
October 12, 2019
Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizes China-based MabPlex International ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page